Opinion|Videos|December 14, 2023
Toxicity Management in Patients With R/R MM Receiving CAR T-Cell Therapy
Key opinion leaders review the management of CAR-T therapy side effects in patients with relapsed/refractory multiple myeloma, including cytokine release syndrome and neurotoxicity, and emphasize the importance of early supervision and known toxicity timing.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5